Area of research
Hepatology · Oncology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Liver Disease Diagnosis and Treatment, and Inflammatory Biomarkers in Disease Prognosis.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study